BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement